NASDAQ:QURE

uniQure Stock Forecast, Price & News

$37.87
-0.35 (-0.92 %)
(As of 09/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$37.40
$38.29
50-Day Range
$26.01
$38.22
52-Week Range
$25.80
$52.19
Volume515,699 shs
Average Volume495,816 shs
Market Capitalization$1.74 billion
P/E Ratio5.94
Dividend YieldN/A
Beta1.22
30 days | 90 days | 365 days | Advanced Chart
Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.


uniQure logo

About uniQure

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.43 out of 5 stars

Medical Sector

158th out of 1,352 stocks

Pharmaceutical Preparations Industry

71st out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











uniQure (NASDAQ:QURE) Frequently Asked Questions

Is uniQure a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last twelve months. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" uniQure stock.
View analyst ratings for uniQure
or view top-rated stocks.

What stocks does MarketBeat like better than uniQure?

Wall Street analysts have given uniQure a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but uniQure wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting uniQure?

uniQure saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 2,220,000 shares, a decrease of 22.1% from the August 15th total of 2,850,000 shares. Based on an average daily volume of 449,100 shares, the days-to-cover ratio is currently 4.9 days. Currently, 6.4% of the shares of the company are short sold.
View uniQure's Short Interest
.

When is uniQure's next earnings date?

uniQure is scheduled to release its next quarterly earnings announcement on Tuesday, October 26th 2021.
View our earnings forecast for uniQure
.

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) posted its quarterly earnings data on Sunday, July, 25th. The biotechnology company reported $8.51 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $2.97 by $5.54. The biotechnology company earned $463.87 million during the quarter, compared to the consensus estimate of $212.65 million. uniQure had a net margin of 60.66% and a trailing twelve-month return on equity of 90.98%.
View uniQure's earnings history
.

How has uniQure's stock price been impacted by Coronavirus (COVID-19)?

uniQure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have decreased by 20.3% and is now trading at $37.87.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for QURE?

12 equities research analysts have issued twelve-month price targets for uniQure's stock. Their forecasts range from $27.46 to $95.00. On average, they expect uniQure's stock price to reach $59.95 in the next year. This suggests a possible upside of 58.3% from the stock's current price.
View analysts' price targets for uniQure
or view top-rated stocks among Wall Street analysts.

Who are uniQure's key executives?

uniQure's management team includes the following people:
  • Matt Kapusta, Chief Executive Officer & Executive Director
  • Pierre Caloz, Chief Operating Officer
  • Christian Klemt, Chief Financial Officer
  • Ricardo Dolmetsch, President-Research & Development
  • Alex Kuta, Executive Vice President-Operations

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure CEO Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among uniQure's employees.

Who are some of uniQure's key competitors?

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Square (SQ) and bluebird bio (BLUE).

What is uniQure's stock symbol?

uniQure trades on the NASDAQ under the ticker symbol "QURE."

Who are uniQure's major shareholders?

uniQure's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (9.58%), Federated Hermes Inc. (7.25%), Invesco Ltd. (6.73%), Point72 Asset Management L.P. (4.07%), Price T Rowe Associates Inc. MD (3.93%) and State Street Corp (3.21%). Company insiders that own uniQure stock include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Ricardo Dolmetsch and Robert Gut.
View institutional ownership trends for uniQure
.

Which major investors are selling uniQure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, BlackRock Inc., Invesco Ltd., Price T Rowe Associates Inc. MD, Maven Securities LTD, Rafferty Asset Management LLC, Federated Hermes Inc., and FMR LLC. Company insiders that have sold uniQure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Matthew C Kapusta, Ricardo Dolmetsch, and Robert Gut.
View insider buying and selling activity for uniQure
or view top insider-selling stocks.

Which major investors are buying uniQure stock?

QURE stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Credit Suisse AG, Marshall Wace North America L.P., Sphera Funds Management LTD., Susquehanna International Group LLP, Antara Capital LP, Tekla Capital Management LLC, and Marshall Wace LLP.
View insider buying and selling activity for uniQure
or or view top insider-buying stocks.

How do I buy shares of uniQure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is uniQure's stock price today?

One share of QURE stock can currently be purchased for approximately $37.87.

How much money does uniQure make?

uniQure has a market capitalization of $1.74 billion and generates $37.51 million in revenue each year. The biotechnology company earns $-125,020,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

How many employees does uniQure have?

uniQure employs 332 workers across the globe.

What is uniQure's official website?

The official website for uniQure is www.uniqure.com.

Where are uniQure's headquarters?

uniQure is headquartered at PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP.

How can I contact uniQure?

uniQure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at (120) 240-6000 or via email at [email protected].


This page was last updated on 9/22/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.